European Medicines Agency approvals of new medicines in September and October 2026
In September and October 2026, the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) recommended the granting of an EU-wide authorisation for 11 new medicines (Table 1) and 4 new biosimilar medicines (Table 2). The CHMP also recommended the authorisation of 3 new generic medicines and new indications for 16 medicines already authorised in the EU.1,2
Authors
- Steffen Thirstrup (ORCID: https://orcid.org/0000-0003-0903-682X)
- Juan García Burgos (ORCID: https://orcid.org/0009-0008-1298-1105)
- Bruno Miguel Nogueira Sepodes (ORCID: https://orcid.org/0000-0002-2761-0955)
Institutions
- European Medicines Agency (NL)
- University of Lisbon (PT)
Publication Details
- Journal
- The Lancet Regional Health - Europe
- Published
- 2026-11-09
- DOI
- https://doi.org/10.1016/j.lanepe.2026.101920
- Primary Topic
- Pharmaceutical Economics and Policy
- Type
- article
- Field-Weighted Citation Impact
- 0.00